This report on sterile injectable drugs market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing sterile injectable drugs products as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global sterile injectable drugs market with respect to the leading market segments based on major types, applications, usage, end users, and geographies.
Based on the product type, the sterile injectable drugs market has been segmented into: small and large molecules. In term of indication, it can be segmented into cardiology & metabolic disorders, neurology, oncology, autoimmune, gastroenterology, hematology, pain, infectious diseases and others. On the basis of drug class it can be segmented into monoclonal antibodies, cytokines, peptide hormones, vaccines, peptide antibiotics, insulin, blood factors, immunoglobulin and others,. Each of the market segments have been extensively analyzed based on the market related factors such as increasing adoption rate worldwide, technological advancement, and growing number of use of disposable products in various geographies. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the sterile injectable drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global sterile injectable drugs market.
Geographically, sterile injectable drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides with market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, Porter’s five forces analysis, market strategy overview, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global sterile injectable drugs market.
The key findings section included in the report would assist existing market players in expanding their market shares, and new companies in establishing their presence in the global sterile injectable drugs market. The report also profiles key players operating in the sterile injectable drugs market which are Baxter International Inc., Sanofi, Pfizer Inc., and GlaxoSmithKline plc. AstraZeneca, Gilead, Sciences, Inc., Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., and Novo Nordisk A/S. The global sterile injectable drugs market is dominated by two global vendors that accounts for around 80% share of the global market.
1.1. Report Scope & Market Segmentation
1.2. Preface
1.3. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Acronyms Used
2.3. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Product Overview
4.2. Key Industry Developments
4.3. Sterile Injectable Drugs Market Size (US$ Bn) Forecast
4.4. Market Opportunity Map
4.5. Porter’s Analysis
4.6. Sterile Injectable Drugs Market Outlook
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Regulatory Scenario
5.6. Pipeline Analysis
5.7. Merger Acquisitions & Collaborations
5.8. Brand Analysis
5.9. Top 3 Players
6. Global Sterile injectable Drugs Market Analysis By Type
6.1. Key Findings
6.2. Introduction
6.3. Global Sterile Injectable Drugs Market Value Share Analysis, By Type
6.4. Sterile Injectable Drugs Market Forecast By Type
6.5. Sterile Injectable Drugs Market Analysis, by Type
6.6. Sterile Injectable Drugs Market Attractiveness Analysis, by Type
7. Sterile Injectable Drugs Market Analysis, By Drug Class
7.1. Key Findings
7.2. Introduction
7.3. Sterile Injectable Drugs Market Value Share Analysis, By Drug Class
7.4. Sterile Injectable Drugs Market Forecast, By Drug Class
7.5. Sterile Injectable Drugs Market Analysis, By Drug Class
7.6. Sterile Injectable Drugs Market Attractiveness Analysis, By Drug Class
8. Sterile Injectable Drugs Market Analysis, by Indication
8.1. Key Findings
8.2. Introduction
8.3. Sterile Injectable Drugs Market Value Share Analysis, by Indication
8.4. Sterile Injectable Drugs Market Forecast, by Indication
8.5. Sterile Injectable Drugs Market Analysis, by Indication
8.6. Sterile Injectable Drugs Market Attractiveness Analysis, by Indication
9. Sterile Injectable Drugs Market Analysis, By Distribution Channel
9.1. Key Findings
9.2. Introduction
9.3. Sterile Injectable Drugs Market Value Share Analysis, By Distribution Channel
9.4. Sterile Injectable Drugs Market Forecast, By Distribution Channel
9.5. Sterile Injectable Drugs Market Analysis, By Distribution Channel
9.6. Sterile Injectable Drugs Market Attractiveness Analysis, By Distribution Channel
10. Sterile Injectable Drugs Market Analysis, by Region
10.1. Global Regulatory Scenario
10.2. Sterile Injectable Drugs Market Value Share Analysis, By Region Type
10.3. Sterile Injectable Drugs Market Forecast, By Region Type
10.4. Sterile Injectable Drugs Market Attractiveness Analysis, By Region Type
11. North America Sterile Injectable Drugs Market Analysis
11.1. Key Findings
11.2. North America Sterile Injectable Drugs Market Overview
11.3. North America Sterile Injectable Drugs Market Value Share Analysis, by Country
11.4. North America Sterile Injectable Drugs Market Forecast, by Country
11.5. North America Sterile Injectable Drugs Market Value Share Analysis, By Type
11.6. North America Sterile Injectable Drugs Market Forecast By Type
11.7. North America Sterile Injectable Drugs Market Value Share Analysis, By Drug Class
11.8. North America Sterile Injectable Drugs Market Forecast By Drug Class
11.9. North America Sterile Injectable Drugs Market Value Share Analysis, By Indication
11.10. North America Sterile Injectable Drugs Market Forecast By Indication
11.11. North America Sterile Injectable Drugs Market Value Share Analysis, By Distribution Channel
11.12. North America Sterile Injectable Drugs Market Forecast By Distribution Channel
11.13. North America Market Attractiveness Analysis
11.14. Market Trends
12. Europe Sterile Injectable Drugs Market Analysis
12.1. Key Findings
12.2. Europe Sterile Injectable Drugs Market Overview
12.3. Europe Sterile Injectable Drugs Market Value Share Analysis, by Country
12.4. Europe Sterile Injectable Drugs Market Forecast, by Country
12.5. Europe Sterile Injectable Drugs Market Value Share Analysis, By Type
12.6. Europe Sterile Injectable Drugs Market Forecast By Type
12.7. Europe Sterile Injectable Drugs Market Value Share Analysis, By Drug Class
12.8. Europe Sterile Injectable Drugs Market Forecast By Drug Class
12.9. Europe Sterile Injectable Drugs Market Value Share Analysis, By Indication
12.10. Europe Sterile Injectable Drugs Market Forecast By Indication
12.11. Europe Sterile Injectable Drugs Market Value Share Analysis, By Distribution Channel
12.12. Europe Sterile Injectable Drugs Market Forecast By Distribution Channel
12.13. Europe Market Attractiveness Analysis
12.14. Market Trends
13. Asia Pacific Sterile Injectable Drugs Market Analysis
13.1. Key Findings
13.2. Asia Pacific Sterile Injectable Drugs Market Overview
13.3. Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, by Country
13.4. Asia Pacific Sterile Injectable Drugs Market Forecast, by Country
13.5. Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, By Type
13.6. Asia Pacific Sterile Injectable Drugs Market Forecast By Type
13.7. Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, By Drug Class
13.8. Asia Pacific Sterile Injectable Drugs Market Forecast By Drug Class
13.9. Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, By Indication
13.10. Asia Pacific Sterile Injectable Drugs Market Forecast By Indication
13.11. Asia Pacific Sterile Injectable Drugs Market Value Share Analysis, By Distribution Channel
13.12. Asia Pacific Sterile Injectable Drugs Market Forecast By Distribution Channel
13.13. Asia Pacific Market Attractiveness Analysis
13.14. Market Trends
14. Latin America Sterile Injectable Drugs Market Analysis
14.1. Key Findings
14.2. Latin America Sterile Injectable Drugs Market Overview
14.3. Latin America Sterile Injectable Drugs Market Value Share Analysis, by Country
14.4. Latin America Sterile Injectable Drugs Market Forecast, by Country
14.5. Latin America Sterile Injectable Drugs Market Value Share Analysis, By Type
14.6. Latin America Sterile Injectable Drugs Market Forecast By Type
14.7. Latin America Sterile Injectable Drugs Market Value Share Analysis, By Drug Class
14.8. Latin America Sterile Injectable Drugs Market Forecast By Drug Class
14.9. Latin America Sterile Injectable Drugs Market Value Share Analysis, By Indication
14.10. Latin America Sterile Injectable Drugs Market Forecast By Indication
14.11. Latin America Sterile Injectable Drugs Market Value Share Analysis, By Distribution Channel
14.12. Latin America Sterile Injectable Drugs Market Forecast By Distribution Channel
14.13. Latin America Market Attractiveness Analysis
14.14. Market Trends
15. Middle East & Africa Sterile Injectable Drugs Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Sterile Injectable Drugs Market Overview
15.3. Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, by Country
15.4. Middle East & Africa Sterile Injectable Drugs Market Forecast, by Country
15.5. Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, By Type
15.6. Middle East & Africa Sterile Injectable Drugs Market Forecast By Type
15.7. Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, By Drug Class
15.8. Middle East & Africa Sterile Injectable Drugs Market Forecast By Drug Class
15.9. Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, By Indication
15.10. Middle East & Africa Sterile Injectable Drugs Market Forecast By Indication
15.11. Middle East & Africa Sterile Injectable Drugs Market Value Share Analysis, By Distribution Channel
15.12. Middle East & Africa Sterile Injectable Drugs Market Forecast By Distribution Channel
15.13. Middle East & Africa Market Attractiveness Analysis
15.14. Market Trends
16. Competition Landscape
16.1. Competition Matrix
16.2. Sterile Injectable Drugs Market Share Analysis, by Company, 2016 (Estimated)
16.3. Company Profile
16.4. Baxter International
16.4.1. Company Details
16.4.2. Business Overview
16.4.3. Financial Overview
16.4.4. Strategic Overview
16.4.5. SWOT Analysis
16.5. Sanofi S.A.
16.5.1. Company Details
16.5.2. Business Overview
16.5.3. Financial Overview
16.5.4. Strategic Overview
16.5.5. SWOT Analysis
16.6. Pfizer, Inc.
16.6.1. Company Details
16.6.2. Business Overview
16.6.3. Financial Overview
16.6.4. Strategic Overview
16.6.5. SWOT Analysis
16.7. GlaxoSmithKline Plc.
16.7.1. Company Details
16.7.2. Business Overview
16.7.3. Financial Overview
16.7.4. Strategic Overview
16.7.5. SWOT Analysis
16.8. AstraZeneca
16.8.1. Company Details
16.8.2. Business Overview
16.8.3. Financial Overview
16.8.4. Strategic Overview
16.8.5. SWOT Analysis
16.9. Merck & Co., Inc.
16.9.1. Company Details
16.9.2. Business Overview
16.9.3. Financial Overview
16.9.4. Strategic Overview
16.9.5. SWOT Analysis
16.10. Novartis AG
16.10.1. Company Details
16.10.2. Business Overview
16.10.3. Financial Overview
16.10.4. Strategic Overview
16.10.5. SWOT Analysis
16.11. Johnson & Johnson Services, Inc.
16.11.1. Company Details
16.11.2. Business Overview
16.11.3. Financial Overview
16.11.4. Strategic Overview
16.11.5. SWOT Analysis
16.12. Novo Nordisk A/S
16.12.1. Company Details
16.12.2. Business Overview
16.12.3. Financial Overview
16.12.4. Strategic Overview
16.12.5. SWOT Analysis
16.13. Gilead Sciences, Inc.
16.13.1. Company Details
16.13.2. Business Overview
16.13.3. Financial Overview
16.13.4. Strategic Overview
16.13.5. SWOT Analysis
